Shareholders that lost money on Skyworks Solutions, Inc.(SWKS) should contact Levi & Korsinsky about pending Class Action – SWKS

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Skyworks Solutions, Inc. (“Skyworks” or the “Company”) (NASDAQ: SWKS) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skyworks investors who were adversely affected by alleged securities fraud between July 30, 2024 and February 5, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/skyworks-solutions-inc-lawsuit-submission-form?prid=144216&wire=4 

SWKS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings.  On February 5, 2025, after market close, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025. The Company attributed its results and low guidance to a “competitive landscape” that had “intensified” in recent years. Following this news, the price of Skyworks’ common stock declined dramatically. From a closing market price of $87.08 per share on February 5, 2025, Skyworks’ stock price fell to $65.60 per share on February 6, 2025, a decline of over 24% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Skyworks during the relevant time frame, you have until May 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-skyworks-solutions-incswks-should-contact-levi–korsinsky-about-pending-class-action—swks-302433878.html

SOURCE Levi & Korsinsky, LLP

Shareholders of AppLovin Corporation Should Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights – APP

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AppLovin investors who were adversely affected by alleged securities fraud between May 10, 2023 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/applovin-corporation-lawsuit-submission-form?prid=144219&wire=4

APP investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning AppLovin’s financial growth and stability. Defendants’ statements included, among other things, confidence in AppLovin’s launch of its AXON 2.0 digital ad platform and using “cutting-edge AI technologies” to more efficiently match advertisements to mobile games, in addition to expanding into web-based marketing and e-commerce. Moreover, defendants publicly reported impressive financial results, outlooks, and guidance to investors, all while using dishonest advertising practices.  The truth emerged on February 26, 2025, when analyst research reports emerged stating that AppLovin was reverse engineering and exploiting advertising data from Meta Platforms. The reports further alleged AppLovin was utilizing manipulative practices to artificially inflate their own ad click-through and app download rates, such as by having ads click on themselves or utilizing design gimmicks to trigger forced shadow downloads, erroneously inflating installation numbers and, in turn, its profit figures.  Following this news, the price of AppLovin’s stock declined from $377.06 per share on February 25, 2025 to $331.00 per share on February 26, 2025.

WHAT’S NEXT? If you suffered a loss in AppLovin during the relevant time frame, you have until May 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-of-applovin-corporation-should-contact-levi–korsinsky-before-may-5-2025-to-discuss-your-rights–app-302433886.html

SOURCE Levi & Korsinsky, LLP

Levi & Korsinsky Notifies Geron Corporation Investors of a Class Action Lawsuit and Upcoming Deadline – GERN

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=144221&wire=4

GERN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning defendants’ expectations for the launch and growth potential of Rytelo (imetelstat). Defendants’ statements included, among other things, confidence in Geron’s ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug’s sales.  On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment.   Following this news, the price of Geron’s common stock declined dramatically. From a closing market price of $2.37 per share on February 25, 2025, Geron’s stock price fell to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Geron during the relevant time frame, you have until May 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-geron-corporation-investors-of-a-class-action-lawsuit-and-upcoming-deadline–gern-302433794.html

SOURCE Levi & Korsinsky, LLP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 28, 2025 in Rocket Lab Lawsuit – RKLB

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Rocket Lab USA, Inc. (“Rocket Lab” or the “Company”) (NASDAQ: RKLB) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket Lab investors who were adversely affected by alleged securities fraud between November 12, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/rocket-lab-usa-inc-lawsuit-submission-form?prid=144215&wire=4

RKLB investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Rocket Lab during the relevant time frame, you have until April 28, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-28-2025-in-rocket-lab-lawsuit–rklb-302433778.html

SOURCE Levi & Korsinsky, LLP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 23, 2025 in Atkore Inc. Lawsuit – ATKR

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Atkore Inc. (“Atkore Inc.” or the “Company”) (NYSE: ATKR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Atkore Inc. investors who were adversely affected by alleged securities fraud between August 2, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/atkore-inc-lawsuit-submission-form?prid=144213&wire=4

ATKR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, the Company and its price-fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result, defendants’ positive statements Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT’S NEXT? If you suffered a loss in Atkore Inc. during the relevant time frame, you have until April 23, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-23-2025-in-atkore-inc-lawsuit–atkr-302433759.html

SOURCE Levi & Korsinsky, LLP

Contact Levi & Korsinsky by April 22, 2025 Deadline to Join Class Action Against Semtech Corporation(SMTC)

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Semtech Corporation (“Semtech Corporation” or the “Company”) (NASDAQ: SMTC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Semtech Corporation investors who were adversely affected by alleged securities fraud between August 27, 2024 and February 7, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/semtech-corporation-lawsuit-submission-form?prid=144212&wire=4

SMTC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) its CopperEdge products did not meet the needs of its server rack customer or end users; (2) as a result, the CopperEdge products required certain rack architecture changes; (3) as a result of the foregoing, the Company’s sales of CopperEdge products would not ramp-up during fiscal 2026; (4) as a result, sales of CopperEdge products would be lower-than-expected; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Semtech Corporation during the relevant time frame, you have until April 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-levi–korsinsky-by-april-22-2025-deadline-to-join-class-action-against-semtech-corporationsmtc-302433720.html

SOURCE Levi & Korsinsky, LLP

Lost Money on Quantum Computing Inc.(QUBT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

PR Newswire


NEW YORK
, April 22, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Quantum Computing Inc. (“Quantum Computing Inc.” or the “Company”) (NASDAQ: QUBT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Quantum Computing Inc. investors who were adversely affected by alleged securities fraud between March 30, 2020 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/quantum-computing-inc-lawsuit-submission-form?prid=144214&wire=4

QUBT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants overstated the capabilities of QCI’s quantum computing technologies, products, and/or services; (ii) defendants overstated the scope and nature of QCI’s relationship with NASA, as well as the scope and nature of QCI’s NASA-related contracts and/or subcontracts; (iii) defendants overstated QCI’s progress in developing a thin film lithium niobate, TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company’s TFLN chips; (iv) QCI’s business dealings with Quad M and millionways both qualified as related party transactions; (v) accordingly, QCI’s revenues relied, at least in part, on undisclosed related party transactions; (vi) all the foregoing, once revealed, was likely to have a significant negative impact on QCI’s business and reputation; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Quantum Computing Inc. during the relevant time frame, you have until April 28, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lost-money-on-quantum-computing-incqubt-join-class-action-suit-seeking-recovery–contact-levi–korsinsky-302433777.html

SOURCE Levi & Korsinsky, LLP

Allot Launches New Off-network Cybersecurity Solution, Part of its 360-degree Protection Platform

Hod Hasharon, Israel, April 22, 2025 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence solutions for communication service providers and enterprises, announced today that the company is launching its new OffNetSecure solution and will demo it at the RSA Conference in San Francisco. The new hassle-free solution protects telecom customers against cyberthreats when they are connected to the internet through means other than their provider’s network.

The Allot OffNetSecure solution is an extension of the Allot Secure cybersecurity platform for telecom operators. It provides seamless cyber threat protection for consumer and SMB telecom subscribers when they are not connected to the provider’s network, for example, when connected as a guest to a Wi-Fi network. This type of connectivity also gives the service provider an additional branded channel for staying in touch with the subscriber which, until now, has been a ‘blind spot’ for the provider. As an extension of Allot Secure, OffNetSecure contributes to the 360-degree solution that offers protection against malware, phishing and ransomware attacks.

“Mobile internet access has never been so risky with cyber threats lurking behind any potential tap on the glass. The OffNetSecure solution from Allot completes the circle of protection provided by the unified Allot Secure suite and offers telecom providers a new revenue stream from a service with high adoption rates,” said Angel Fernandez, VP Cybersecurity Products for Allot.

The Allot OffNetSecure solution is implemented on the end customer’s Android smartphones and tablets, Apple iPhones and iPads and is activated as a part of the provider’s branded customer care or other app that is already running on the customer’s device. Unlike endpoint protection clients, Allot OffNetSecure requires no downloading, no installation and no updating by the end customer. Allot OffNetSecure can increase the telecom provider’s revenue by enabling them to create premium plans and offer unified provisioning, policies, configurations and reporting with other Allot Secure products.

You can see the OffNetSecure product demo and talk to Allot product experts at the RSA Conference, April 28th through May 1st at booth #5281.

###

Additional Resources:

Allot Blog: https://www.allot.com/blog
Telco CyberTalk Podcast: https://www.allot.com/resources/podcasts
Follow us on Twitter: @allot_ltd
Follow us on LinkedIn: https://www.linkedin.com/company/allot-communications

About Allot

Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a provider of leading innovative converged cybersecurity solutions and network intelligence for service providers and enterprises worldwide, enhancing value to their customers. Our solutions are deployed globally for network-native cybersecurity services, network and application analytics, traffic control and shaping, and more. Allot’s multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Our industry-leading network-native security-as-a-service solution is already used by many millions of subscribers globally.

Allot. See. Control. Secure.

Forward-Looking Statement

This release contains forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied in such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our accounts receivables, including our ability to collect outstanding accounts and assess their collectability on a quarterly basis; our ability to meet expectations with respect to our financial guidance and outlook; our ability to compete successfully with other companies offering competing technologies; the loss of one or more significant customers; consolidation of, and strategic alliances by, our competitors; government regulation; the timing of completion of key project milestones which impact the timing of our revenue recognition; lower demand for key value-added services; our ability to keep pace with advances in technology and to add new features and value-added services; managing lengthy sales cycles; operational risks associated with large projects; our dependence on fourth party channel partners for a material portion of our revenues; and other factors discussed under the heading “Risk Factors” in the Company’s annual report on Form 20-F filed with the Securities and Exchange Commission. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.



Seth Greenberg
Allot
+972 54 922 2294
[email protected]

Ehud Helft
Allot Investor Relations
+1-212-378-8040
[email protected]

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse

Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts

Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement

PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10, for the treatment of oral lichen planus (OLP). The Company also recently reported full enrollment across all three planned dose cohorts.

Treatment with LP-310 at the 0.50 mg dose demonstrated statistically significant improvements in multiple patient-reported and investigator-measured efficacy endpoints, reinforcing LP-310’s potential as a non-steroidal, locally delivered therapy for OLP. The trial, currently active across seven U.S. study sites, has now progressed to the third and highest dose cohort (1.0 mg/10 mL), with topline results expected in the second quarter of 2025.

“These results mark meaningful progress for LP-310 and further strengthen our confidence in its clinical and commercial potential,” said Jonathan Kaufman, Co-Founder and Chief Executive Officer of Lipella Pharmaceuticals. “With the Phase 2a trial now fully enrolled and final data expected this quarter, we are advancing toward key value-driving milestones, including a Phase 2b IND submission and broader regulatory engagement to support the program’s continued development.”

Topline Findings from the 0.50 mg Cohort:

  • Investigator Global Assessment (IGA): Improved from 3.42 ± 0.21 at baseline to 2.71 ± 0.30 at week 1 (p=0.029), 1.71 ± 0.43 at week 4 (p=0.007) and 2.75 ± 0.34 at week 6 (p=0.112).
  • Reticulation, Erythema and Ulceration (REU) Score: Reduced from 26.91 ± 2.54 at baseline to 17.02 ± 2.36 at week 1 (p=0.003), 11.88 ± 2.91 at week 4 (p=0.003) and 18.47 ± 4.12 at week 6 (p=0.028).
  • Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0.028).
  • Pain Numerical Rating Scale (NRS): Improved from 6.42 ± 0.75 at baseline to 4.25 ± 0.89 at week 1 (p=0.003), 2.25 ± 1.09 at week 4 (p=0.003) and 3.52 ± 1.51 at week 6 (p=0.028).
  • Global Response Assessment (GRA): Significant improvement was observed at week 4 (p=0.028).

Safety and Tolerability

LP-310 continues to be well tolerated, with no treatment-related SAEs and no patient dropouts. All participants successfully adhered to the twice-daily 10-milliliter rinse regimen. Pharmacokinetic analysis confirmed that tacrolimus levels remained undetectable or minimal in all patients, reinforcing LP-310’s ability to deliver localized benefits without systemic toxicity.

“We’re very encouraged by the positive data from the 0.50 mg cohort, which demonstrated statistically significant efficacy across multiple clinical measures while maintaining a strong safety profile,” said Dr. Michael Chancellor, Co-Founder and Chief Medical Officer of Lipella Pharmaceuticals. “Oral lichen planus is a painful, chronic condition with no FDA-approved treatment and limited therapeutic options. The symptom relief reported by patients, along with reductions in inflammation and ulceration, highlights LP-310’s potential to be a transformative, steroid-free, and easy-to-use therapy that addresses a longstanding clinical unmet need and improves quality of life.”

Next Steps in Development

With enrollment now complete across all three dose cohorts, Lipella is positioned to deliver final topline data from the 1.0 mg cohort in Q2 2025. These data are expected to form the foundation for upcoming regulatory interactions and next-phase clinical advancement. Key development milestones include:

  • Reporting final phase 2a topline results in Q2 2025
  • Advancing discussions with regulatory agencies including submission of an Investigational New Drug (IND) application for a Phase 2b trial in late 2025
  • Preparing to pursue FDA Breakthrough Therapy designation request

About LP-310

LP-310 is an innovative oral rinse formulation of LP-10 (tacrolimus), developed to address OLP. Designed to provide localized therapeutic effects while minimizing systemic exposure, LP-310 offers a promising new approach to managing this painful and often debilitating condition.

A Phase 2a multicenter, dose-ranging clinical trial is currently underway to evaluate the safety, tolerability and efficacy of LP-310 in adult participants with symptomatic OLP. The trial includes three dose levels (0.25 mg, 0.5 mg and 1.0 mg of tacrolimus) and is being conducted across seven active U.S. sites, which are now recruiting participants. Lipella has reported topline data from the first two cohorts (0.25 mg and 0.50 mg), with the final cohort (1.0 mg) currently enrolling. Topline results from the 1.0 mg cohort are expected in the first half of 2025.

For more information about the study or to participate, visit https://lipella.com/oral-lichen-planus-treatment/ or https://clinicaltrials.gov/study/NCT06233591.

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on and LinkedIn.

Forward-Looking Statements

This press release includes certain “forward-looking statements” which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “potential,” “target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “predicts,” “expects,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, the current clinical trial results for LP-310 and our other products general capital market risks, our ability to regain and maintain compliance with the listing standards of The Nasdaq Stock Market LLC, regional, national or global political, economic, business, competitive, market and regulatory conditions, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax or investment advice and should consult with your own advisors as to the matters described herein, as applicable.

CONTACT

Jonathan Kaufman
Chief Executive Officer
Lipella Pharmaceuticals Inc.
[email protected]
1-412-894-1853

PCG Advisory
Jeff Ramson
[email protected]



Mercantile Bank Corporation Announces Strong First Quarter 2025 Results

PR Newswire

Growth in net interest income, notable increases in certain noninterest income categories, sustained strength in asset quality metrics, and continuing solid capital position highlight the quarter


GRAND RAPIDS, Mich.
, April 22, 2025 /PRNewswire/ — Mercantile Bank Corporation (NASDAQ: MBWM) (“Mercantile”) reported net income of $19.5 million, or $1.21 per diluted share, for the first quarter of 2025, compared with net income of $21.6 million, or $1.34 per diluted share, for the first quarter of 2024.

“We are pleased to report sustained strength in financial metrics during the first quarter of 2025.  We believe these results continue to evidence our ability to effectively manage challenges emanating from ongoing uncertain economic and operating environments,” said Ray Reitsma, President and Chief Executive Officer of Mercantile.  “The strong operating performance reflected net interest income expansion, a steadying net interest margin, higher levels of treasury management, mortgage banking, and payroll service income, and continuing strength in asset quality metrics.  Notably, net growth in various local deposit relationships and newly established deposit relationships substantially offset customary seasonal deposit withdrawals, and we remain committed to lowering our loan-to-deposit ratio through local deposit generation.”

First quarter highlights include:

  • Net interest income expansion
  • Noteworthy increases in treasury management, mortgage banking, and payroll income
  • Net growth in various local deposit relationships and new local deposit relationships largely offset customary seasonal deposit withdrawals
  • Continuing low levels of nonperforming assets, past due loans, and loan charge-offs
  • Strong capital position

Operating Results

Net revenue, consisting of net interest income and noninterest income, was $57.2 million during the first quarter of 2025, down $1.0 million, or 1.7 percent, from $58.2 million during the prior-year first quarter.  Net interest income during the first three months of 2025 was $48.6 million, up $1.2 million, or 2.5 percent, from $47.4 million during the respective 2024 period as growth in earning assets more than offset a lower net interest margin.  Noninterest income totaled $8.7 million during the first quarter of 2025, compared to $10.9 million during the first quarter of 2024.  Higher levels of treasury management fees, mortgage banking income, and payroll service fees were more than offset by declines in interest rate swap income, revenue generated from an investment in a private equity fund, and bank owned life insurance income.

The net interest margin was 3.47 percent in the first quarter of 2025, down from 3.74 percent in the prior-year first quarter.  The yield on average earning assets was 5.74 percent during the current-year first quarter, a decrease from 6.06 percent during the respective 2024 period.  The lower yield primarily resulted from a decreased yield on loans and a change in earning asset mix, which more than offset an enhanced yield on securities stemming from reinvestment and portfolio expansion activities in a higher interest rate environment.  The yield on loans was 6.31 percent during the first quarter of 2025, down from 6.65 percent during the first quarter of 2024 mainly due to lower interest rates on variable-rate commercial loans resulting from the Federal Open Market Committee (“FOMC”) lowering the targeted federal funds rate.  The FOMC decreased the targeted federal funds rate by 50 basis points in September of 2024 and 25 basis points in each of November and December of 2024, during which time average variable-rate commercial loans represented approximately 73 percent of average total commercial loans.  Signifying the success of a strategic initiative to reduce the loan-to-deposit ratio and increase on-balance sheet liquidity, higher-yielding loans represented a reduced percentage of earning assets and lower-yielding securities and interest-earning deposits accounted for increased percentages of earning assets in the first quarter of 2025 compared to the first quarter of 2024.

During the first quarter of 2025, the cost of funds was 2.27 percent, down from 2.32 percent in the first quarter of 2024 mainly due to lower rates paid on money market accounts, reflecting the decreased interest rate environment that began in September of 2024 in conjunction with the FOMC’s lowering of the targeted federal funds rate.  A change in funding mix, primarily consisting of a decline in average noninterest-bearing checking accounts and growth in average higher-cost money market accounts and time deposits, negatively impacted the cost of funds during the first three months of 2025.  The increases in money market accounts and time deposits reflected new deposit relationships, growth in existing deposit relationships, and deposit migration.

Mercantile recorded provisions for credit losses of $2.1 million and $1.3 million during the first quarters of 2025 and 2024, respectively.  The provision expense recorded during the current-year first quarter primarily reflected an increased allocation necessitated by changes to the economic forecast.  The provision expense recorded during the first quarter of 2024 mainly reflected an individual allocation for a nonperforming commercial loan relationship, allocations necessitated by net loan growth, and a change in a commercial loan environmental factor, which more than offset the impacts of an improved economic forecast and changes to the loan portfolio composition. The recording of net loan recoveries and sustained strength in loan quality metrics during both periods largely mitigated additional reserves associated with loan growth.

Noninterest income totaled $8.7 million during the first quarter of 2025, down from $10.9 million during the respective 2024 period as growth in treasury management fees, mortgage banking income, and payroll service fees was more than offset by lower levels of interest rate swap income, revenue generated from an investment in a private equity fund, and bank owned life insurance income.  The higher level of mortgage banking income mainly resulted from increases in the percentage of loans originated with the intent to sell, which equaled approximately 80 percent during the current-year first quarter compared to approximately 74 percent during the first quarter of 2024, and total loan originations, which were up approximately 26 percent during the first quarter of 2025 compared to the corresponding 2024 period.  During the first quarter of 2025, interest rate swap income, which sometimes varies greatly from period to period due to the timing of closing transactions, was negatively impacted by the ongoing uncertainty surrounding economic and operating conditions and the associated reduction in commercial loan activity. Noninterest income during the first three months of 2024 included bank owned life insurance claims totaling $0.7 million.

Noninterest expense totaled $31.1 million during the first quarter of 2025, compared to $29.9 million during the prior-year first quarter.  The increase primarily resulted from higher salary and benefit costs, largely reflecting annual merit pay increases and market adjustments.  A higher level of data processing costs, mainly reflecting increased software support costs, also contributed to the rise in noninterest expense.  Noninterest expense during the first quarter of 2024 included contributions to The Mercantile Bank Foundation totaling $0.7 million.

Mr. Reitsma commented, “The notable increase in mortgage banking income during the first quarter of 2025 primarily reflected the ongoing success of planned initiatives to amplify the percentage of loans originated with the intent to sell and maintain solid loan production.  We are pleased with the growth in treasury management and payroll service fees, largely reflecting customers’ increased use of products and services and our sales team’s effectiveness in marketing them to existing and new clients.  Although declining as anticipated from the first quarter of 2024 due to a lower yield on average earning assets, our net interest margin has remained relatively steady during the past three quarters.  The impact of the lower net interest margin was more than offset by growth in earning assets, providing for an increase in net interest income.  We remain committed to expanding the balance sheet in a cost-effective manner and continually examine our operating segments to identify opportunities to function more efficiently while continuing to deliver outstanding service to our customers and provide them with market-leading products and services to meet their needs.”

Balance Sheet

As of March 31, 2025, total assets were $6.14 billion, up $89.0 million from December 31, 2024.  Total loans increased $35.8 million, or an annualized 3.2 percent, during the first quarter of 2025, primarily reflecting growth in commercial loans of $44.3 million.  Commercial loans grew an annualized 4.8 percent during the current-year first quarter despite the full payoffs and partial paydowns of certain larger relationships, which aggregated approximately $55 million during the period.  The payoffs and paydowns mainly stemmed from customers using excess cash flows generated within their operations to make line of credit reductions, as well as from sales of assets.  Residential mortgage loans declined $10.4 million, and other consumer loans were up $1.9 million during the first three months of 2025.  During the first quarter of 2025, securities available for sale grew $57.2 million, and interest-earning deposits declined $20.9 million.

As of March 31, 2025, unfunded commitments on commercial construction and development loans, which are expected to be funded over the next 12 to 18 months, and residential construction loans, which are expected to be largely funded over the next 12 months, totaled $210 million and $30 million, respectively.

Commercial and industrial loans and owner-occupied commercial real estate loans combined represented approximately 54 percent of total commercial loans as of March 31, 2025, a level that has remained relatively consistent with prior periods and in line with our expectations.

Total deposits as of March 31, 2025, were $4.68 billion, down $16.6 million, or 0.4 percent, from December 31, 2024, but were up $674 million, or 16.8 percent, from March 31, 2024.  Local deposits decreased $16.6 million during the first quarter of 2025, while brokered deposits were essentially unchanged.  The slight reduction in local deposits during the current-year first quarter primarily resulted from the customary level of seasonal noninterest-bearing deposit withdrawals by customers to make bonus and tax payments and partnership distributions, the impact of which was substantially offset by net growth in various existing deposit relationships and new client acquisitions.  The decrease in total deposits and loan portfolio expansion during the first three months of 2025 resulted in a nominal increase in the loan-to-deposit ratio from 98 percent at year-end 2024 to 99 percent as of March 31, 2025.  As of March 31, 2024, the loan-to-deposit ratio was 108 percent.  Wholesale funds were $516 million and $537 million as of March 31, 2025, and December 31, 2024, respectively, with both amounts representing approximately 10 percent of total funds as of the respective dates.  Noninterest-bearing checking accounts represented approximately 25 percent of total deposits as of March 31, 2025.

Mr. Reitsma noted, “The commercial loan portfolio grew during the first quarter of 2025 notwithstanding partial paydowns and full payoffs and a decline in commercial lending activities stemming from the ongoing uncertain economic and operating environments.  Based on our current pipeline and ongoing discussions with current and prospective borrowers, we believe ample opportunities to originate commercial loans will be available in future periods.  Our near-term objective remains to grow our local deposit base in an effort to lower our loan-to-deposit ratio while limiting the use of wholesale funds to fund loan originations and investment purchases.”

Asset Quality

Nonperforming assets totaled $5.4 million, or less than 0.1 percent of total assets, at March 31, 2025, compared to $5.7 million, or less than 0.1 percent of total assets, at December 31, 2024, and $6.2 million, or 0.1 percent of total assets, at March 31, 2024.  The level of past due loans remains nominal.  During the first quarter of 2025, loan charge-offs totaled $0.1 million, while recoveries of prior period loan charge-offs equaled $0.2 million, providing for net loan recoveries of $0.1 million, or an annualized 0.01 percent of average total loans.

Mr. Reitsma remarked, “As evidenced by the sustained strength in asset quality metrics during the first quarter of 2025, including ongoing low levels of nonperforming assets, past due loans, and loan charge-offs, we remain committed to underwriting loans in a proper and disciplined manner.  The early detection and reporting of weakening commercial credit relationships and developing sector-specific or systemic credit issues remain top priorities, and we believe our continuing focus on the use of these important credit monitoring tools will limit the impact of such on our overall financial condition.  Our residential mortgage loan and consumer loan portfolios continue to perform well, with both portfolios exhibiting low delinquency and charge-off levels.”

Capital Position

Shareholders’ equity totaled $608 million as of March 31, 2025, up $23.8 million from December 31, 2024.  Mercantile Bank maintained “well-capitalized” positions at the end of the first quarter of 2025 and year-end 2024, with a total risk-based capital ratio of 14.0 percent and 13.9 percent, respectively.  As of March 31, 2025, Mercantile Bank had approximately $217 million in excess of the 10 percent minimum regulatory threshold required to be categorized as a “well-capitalized” institution. 

All of Mercantile Bank’s investments are categorized as available-for-sale.  As of March 31, 2025, the net unrealized loss on these investments totaled $51.5 million, resulting in an after-tax reduction to equity capital of $40.7 million.  As of December 31, 2024, the net unrealized loss on these investments totaled $63.1 million, resulting in an after-tax reduction to equity capital of $49.8 million.  Although unrealized gains and losses on investments are excluded from regulatory capital ratio calculations, Mercantile Bank’s excess capital over the minimum regulatory requirement to be considered a “well-capitalized” institution would approximate $178 million on an adjusted basis as of March 31, 2025.

Mercantile reported 16,235,660 total shares outstanding as of March 31, 2025.

Mr. Reitsma concluded, “Our ongoing financial strength has enabled us to continue our regular cash dividend program and provide shareholders with meaningful cash returns on their investments.  We believe our strong capital position, operating results, and asset quality metrics will allow us to effectively address potential issues arising from shifting economic and operating conditions.  Our community banking philosophy and passionate focus on meeting customers’ needs have been instrumental in retaining existing relationships and securing new relationships, and we believe these inherent traits will be key components of our efforts to reduce our loan-to-deposit ratio through local deposit generation.”

Investor Presentation

Mercantile has prepared presentation materials that management intends to use during its previously announced first quarter 2025 conference call on Tuesday, April 22, 2025, at 10:00 a.m. Eastern Time, and from time to time thereafter in presentations about the company’s operations and performance.  These materials, which are available for viewing in the Investor Relations section of Mercantile’s website at www.mercbank.com, have been furnished to the U.S. Securities and Exchange Commission concurrently with this press release.

About Mercantile Bank Corporation

Based in Grand Rapids, Michigan, Mercantile Bank Corporation is the bank holding company for Mercantile Bank. Mercantile provides financial products and services in a professional and personalized manner designed to make banking easier for businesses, individuals, and governmental units. Distinguished by exceptional service, knowledgeable staff, and a commitment to the communities it serves, Mercantile is one of the largest Michigan-based banks with assets of approximately $6.1 billion. Mercantile Bank Corporation’s common stock is listed on the NASDAQ Global Select Market under the symbol “MBWM.”  For more information about Mercantile, visit www.mercbank.com, and follow us on Facebook, Instagram, X (formerly Twitter) @MercBank, and LinkedIn @merc-bank.

Forward-Looking Statements

This news release contains statements or information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods.  Any such statements are based on current expectations that involve a number of risks and uncertainties.  Actual results may differ materially from the results expressed in forward-looking statements.  Factors that might cause such a difference include changes in interest rates and interest rate relationships; increasing rates of inflation and slower growth rates or recession; significant declines in the value of commercial real estate; market volatility; demand for products and services; climate impacts; labor markets; the degree of competition by traditional and nontraditional financial services companies; changes in banking regulation or actions by bank regulators; changes in tax laws and other laws and regulations applicable to us; changes in prices, levies, and assessments; the impact of technological advances; potential cyber-attacks, information security breaches and other criminal activities; litigation liabilities; governmental and regulatory policy changes; the outcomes of existing or future contingencies; trends in customer behavior as well as their ability to repay loans; changes in local real estate values; damage to our reputation resulting from adverse publicity, regulatory actions, litigation, operational failures, and the failure to meet client expectations and other facts; changes in the national and local economies; unstable political and economic environments; disease outbreaks, such as the COVID-19 pandemic or similar public health threats, and measures implemented to combat them; and other factors, including those expressed as risk factors, disclosed from time to time in filings made by Mercantile with the Securities and Exchange Commission.  Mercantile undertakes no obligation to update or clarify forward-looking statements, whether as a result of new information, future events or otherwise.  Investors are cautioned not to place undue reliance on any forward-looking statements contained herein.

Mercantile Bank Corporation

First Quarter 2025 Results

MERCANTILE BANK CORPORATION

CONSOLIDATED BALANCE SHEETS

MARCH 31,

DECEMBER 31,

MARCH 31,


2025


2024


2024

(Unaudited)

(Audited)

(Unaudited)


ASSETS

   Cash and due from banks

$

70,320,000

$

56,991,000

$

52,606,000

   Interest-earning deposits

315,140,000

336,019,000

184,625,000

      Total cash and cash equivalents

385,460,000

393,010,000

237,231,000

   Securities available for sale

787,583,000

730,352,000

609,153,000

   Federal Home Loan Bank stock

21,513,000

21,513,000

21,513,000

   Mortgage loans held for sale

15,192,000

15,824,000

14,393,000

   Loans

4,636,549,000

4,600,781,000

4,322,006,000

   Allowance for credit losses

(56,666,000)

(54,454,000)

(51,638,000)

      Loans, net

4,579,883,000

4,546,327,000

4,270,368,000

   Premises and equipment, net

53,693,000

53,427,000

50,835,000

   Bank owned life insurance

94,417,000

93,839,000

85,528,000

   Goodwill

49,473,000

49,473,000

49,473,000

   Other assets

153,986,000

148,396,000

127,459,000

      Total assets

$

6,141,200,000

$

6,052,161,000

$

5,465,953,000


LIABILITIES AND SHAREHOLDERS’ EQUITY

   Deposits:

      Noninterest-bearing

$

1,173,499,000

$

1,264,523,000

$

1,134,995,000

      Interest-bearing

3,508,286,000

3,433,843,000

2,872,815,000

         Total deposits

4,681,785,000

4,698,366,000

4,007,810,000

   Securities sold under agreements to repurchase

242,102,000

121,521,000

228,618,000

   Federal Home Loan Bank advances

366,221,000

387,083,000

447,083,000

   Subordinated debentures

50,501,000

50,330,000

49,815,000

   Subordinated notes

89,400,000

89,314,000

89,057,000

   Accrued interest and other liabilities

102,845,000

121,021,000

106,926,000

         Total liabilities

5,532,854,000

5,467,635,000

4,929,309,000


SHAREHOLDERS’ EQUITY

   Common stock

300,732,000

299,705,000

296,065,000

   Retained earnings

348,281,000

334,646,000

293,554,000

   Accumulated other comprehensive income/(loss)

(40,667,000)

(49,825,000)

(52,975,000)

      Total shareholders’ equity

608,346,000

584,526,000

536,644,000

      Total liabilities and shareholders’ equity

$

6,141,200,000

$

6,052,161,000

$

5,465,953,000

 

Mercantile Bank Corporation

First Quarter 2025 Results

MERCANTILE BANK CORPORATION

CONSOLIDATED REPORTS OF INCOME

(Unaudited)

THREE MONTHS ENDED

THREE MONTHS ENDED



March 31, 2025



March 31, 2024


INTEREST INCOME

   Loans, including fees

$

71,992,000

$

71,270,000

   Investment securities

5,411,000

3,421,000

   Interest-earning deposits

2,935,000

2,033,000

      Total interest income

80,338,000

76,724,000


INTEREST EXPENSE

   Deposits

25,192,000

22,224,000

   Short-term borrowings

1,763,000

1,654,000

   Federal Home Loan Bank advances

2,898,000

3,399,000

   Other borrowed money

1,937,000

2,086,000

      Total interest expense

31,790,000

29,363,000


      Net interest income

48,548,000

47,361,000

Provision for credit losses

2,100,000

1,300,000


      Net interest income after


         provision for credit losses

46,448,000

46,061,000


NONINTEREST INCOME

   Service charges on accounts

1,839,000

1,531,000

   Mortgage banking income

2,651,000

2,343,000

   Credit and debit card income

2,201,000

2,121,000

   Interest rate swap income

80,000

1,339,000

   Payroll services

1,040,000

896,000

   Earnings on bank owned life insurance

543,000

1,172,000

   Other income

348,000

1,466,000

      Total noninterest income

8,702,000

10,868,000


NONINTEREST EXPENSE

   Salaries and benefits

19,557,000

18,237,000

   Occupancy

2,118,000

2,289,000

   Furniture and equipment

787,000

929,000

   Data processing costs

3,770,000

3,289,000

   Charitable foundation contributions

3,000

703,000

   Other expense

4,869,000

4,497,000

      Total noninterest expense

31,104,000

29,944,000


      Income before federal income


         tax expense

24,046,000

26,985,000

Federal income tax expense

4,509,000

5,423,000


      Net Income

$

19,537,000

$

21,562,000

   Basic earnings per share

$1.21

$1.34

   Diluted earnings per share

$1.21

$1.34

   Average basic shares outstanding

16,197,978

16,118,858

   Average diluted shares outstanding

16,197,978

16,118,858

 

Mercantile Bank Corporation

First Quarter 2025 Results

MERCANTILE BANK CORPORATION

CONSOLIDATED FINANCIAL HIGHLIGHTS

(Unaudited)


Quarterly


(dollars in thousands except per share data)


2025


2024


2024


2024


2024


1st Qtr


4th Qtr


3rd Qtr


2nd Qtr


1st Qtr


EARNINGS

   Net interest income

$

48,548

48,361

48,292

47,072

47,361

   Provision for credit losses

$

2,100

1,500

1,100

3,500

1,300

   Noninterest income

$

8,702

10,172

9,667

9,681

10,868

   Noninterest expense

$

31,104

33,806

32,303

29,737

29,944

   Net income before federal income

      tax expense

$

24,046

23,227

24,556

23,516

26,985

   Net income

$

19,537

19,626

19,618

18,786

21,562

   Basic earnings per share

$

1.21

1.22

1.22

1.17

1.34

   Diluted earnings per share

$

1.21

1.22

1.22

1.17

1.34

   Average basic shares outstanding

16,197,978

16,142,578

16,138,320

16,122,813

16,118,858

   Average diluted shares outstanding

16,197,978

16,142,578

16,138,320

16,122,813

16,118,858


PERFORMANCE RATIOS

   Return on average assets

1.32 %

1.30 %

1.35 %

1.36 %

1.61 %

   Return on average equity

13.34 %

13.36 %

13.73 %

13.93 %

16.41 %

   Net interest margin (fully tax-equivalent)

3.47 %

3.41 %

3.52 %

3.63 %

3.74 %

   Efficiency ratio

54.33 %

57.76 %

55.73 %

52.40 %

51.42 %

   Full-time equivalent employees

662

668

653

670

642


YIELD ON ASSETS / COST OF FUNDS

   Yield on loans

6.31 %

6.41 %

6.69 %

6.64 %

6.65 %

   Yield on securities

2.79 %

2.62 %

2.43 %

2.30 %

2.20 %

   Yield on interest-earning deposits

4.40 %

4.66 %

5.37 %

5.28 %

5.35 %

   Yield on total earning assets

5.74 %

5.81 %

6.08 %

6.07 %

6.06 %

   Yield on total assets

5.42 %

5.49 %

5.73 %

5.72 %

5.72 %

   Cost of deposits

2.23 %

2.36 %

2.52 %

2.42 %

2.25 %

   Cost of borrowed funds

3.62 %

3.73 %

3.75 %

3.56 %

3.51 %

   Cost of interest-bearing liabilities

3.08 %

3.30 %

3.53 %

3.40 %

3.27 %

   Cost of funds (total earning assets)

2.27 %

2.40 %

2.56 %

2.44 %

2.32 %

   Cost of funds (total assets)

2.14 %

2.27 %

2.41 %

2.31 %

2.19 %


MORTGAGE BANKING ACTIVITY

   Total mortgage loans originated

$

100,396

121,010

160,944

122,728

79,930

   Purchase/construction mortgage loans originated

$

81,494

82,212

122,747

103,939

57,668

   Refinance mortgage loans originated

$

18,902

38,798

38,197

18,789

22,262

   Mortgage loans originated with intent to sell

$

80,453

100,628

128,678

91,490

59,280

   Income on sale of mortgage loans

$

2,455

3,768

3,376

2,487

2,064


CAPITAL

   Tangible equity to tangible assets

9.17 %

8.91 %

9.10 %

9.03 %

8.99 %

   Tier 1 leverage capital ratio

10.75 %

10.60 %

10.68 %

10.85 %

10.88 %

   Common equity risk-based capital ratio

10.90 %

10.66 %

10.53 %

10.46 %

10.41 %

   Tier 1 risk-based capital ratio

11.78 %

11.54 %

11.42 %

11.36 %

11.33 %

   Total risk-based capital ratio

14.44 %

14.17 %

14.13 %

14.10 %

14.05 %

   Tier 1 capital

$

647,795

633,134

618,038

602,835

587,888

   Tier 1 plus tier 2 capital

$

794,143

777,857

764,653

748,097

729,410

   Total risk-weighted assets

$

5,499,046

5,487,886

5,411,628

5,306,911

5,190,106

   Book value per common share

$

37.47

36.20

36.14

34.15

33.29

   Tangible book value per common share

$

34.42

33.14

33.07

31.09

30.22

   Cash dividend per common share

$

0.37

0.36

0.36

0.35

0.35


ASSET QUALITY

   Gross loan charge-offs

$

63

3,787

10

26

15

   Recoveries

$

175

150

92

296

439

   Net loan charge-offs (recoveries)

$

(112)

3,637

(82)

(270)

(424)

   Net loan charge-offs (recoveries) to average loans

(0.01 %)

0.31 %

(0.01 %)

(0.02 %)

(0.04 %)

   Allowance for credit losses

$

56,666

54,454

56,590

55,408

51,638

   Allowance to loans

1.22 %

1.18 %

1.24 %

1.25 %

1.19 %

   Nonperforming loans

$

5,361

5,743

9,877

9,129

6,040

   Other real estate/repossessed assets

$

0

0

0

0

200

   Nonperforming loans to total loans

0.12 %

0.12 %

0.22 %

0.21 %

0.14 %

   Nonperforming assets to total assets

0.09 %

0.09 %

0.17 %

0.16 %

0.11 %


NONPERFORMING ASSETS – COMPOSITION

   Residential real estate:

      Land development

$

95

97

100

1

1

      Construction

$

0

0

0

0

0

      Owner occupied / rental

$

2,968

2,878

3,008

2,288

3,370

   Commercial real estate:

      Land development

$

0

0

0

0

0

      Construction

$

0

0

0

0

0

      Owner occupied  

$

41

42

0

0

200

      Non-owner occupied

$

0

0

0

0

0

   Non-real estate:

      Commercial assets

$

2,257

2,726

6,769

6,840

2,669

      Consumer assets

$

0

0

0

0

0

   Total nonperforming assets

$

5,361

5,743

9,877

9,129

6,240


NONPERFORMING ASSETS – RECON

   Beginning balance

$

5,743

9,877

9,129

6,240

3,615

   Additions

$

423

224

906

4,570

2,802

   Return to performing status

$

0

(102)

0

0

0

   Principal payments

$

(744)

(515)

(158)

(1,481)

(177)

   Sale proceeds

$

0

0

0

(200)

0

   Loan charge-offs

$

(61)

(3,741)

0

0

0

   Valuation write-downs

$

0

0

0

0

0

   Ending balance

$

5,361

5,743

9,877

9,129

6,240


LOAN PORTFOLIO COMPOSITION

   Commercial:

      Commercial & industrial

$

1,314,383

1,287,308

1,312,774

1,275,745

1,222,638

      Land development & construction

$

68,790

66,936

66,374

76,247

75,091

      Owner occupied comm’l R/E

$

705,645

748,837

746,714

732,844

719,338

      Non-owner occupied comm’l R/E

$

1,183,728

1,128,404

1,095,988

1,059,052

1,045,614

      Multi-family & residential rental

$

479,045

475,819

426,438

389,390

366,961

         Total commercial

$

3,751,591

3,707,304

3,648,288

3,533,278

3,429,642

   Retail:

      1-4 family mortgages

$

817,212

827,597

844,093

849,626

840,653

      Other consumer

$

67,746

65,880

60,637

55,341

51,711

         Total retail

$

884,958

893,477

904,730

904,967

892,364

         Total loans

$

4,636,549

4,600,781

4,553,018

4,438,245

4,322,006


END OF PERIOD BALANCES

   Loans

$

4,636,549

4,600,781

4,553,018

4,438,245

4,322,006

   Securities

$

809,096

751,865

724,888

669,420

630,666

   Other interest-earning assets

$

315,140

336,019

240,780

135,766

184,625

   Total earning assets (before allowance)

$

5,760,785

5,688,665

5,518,686

5,243,431

5,137,297

   Total assets

$

6,141,200

6,052,161

5,917,127

5,602,388

5,465,953

   Noninterest-bearing deposits

$

1,173,499

1,264,523

1,182,219

1,119,888

1,134,995

   Interest-bearing deposits

$

3,508,286

3,433,843

3,273,679

3,026,686

2,872,815

   Total deposits

$

4,681,785

4,698,366

4,455,898

4,146,574

4,007,810

   Total borrowed funds

$

749,711

649,528

778,669

789,327

815,744

   Total interest-bearing liabilities

$

4,257,997

4,083,371

4,052,348

3,816,013

3,688,559

   Shareholders’ equity

$

608,346

584,526

583,311

551,151

536,644


AVERAGE BALANCES

   Loans

$

4,629,098

4,565,837

4,467,365

4,396,475

4,299,163

   Securities

$

784,608

742,145

699,872

640,627

634,099

   Other interest-earning assets

$

266,871

330,490

284,187

182,636

150,234

   Total earning assets (before allowance)

$

5,680,577

5,638,472

5,451,424

5,219,738

5,083,496

   Total assets

$

6,018,158

5,967,036

5,781,111

5,533,262

5,384,675

   Noninterest-bearing deposits

$

1,144,781

1,188,561

1,191,642

1,139,887

1,175,884

   Interest-bearing deposits

$

3,443,770

3,335,477

3,145,799

2,957,011

2,790,308

   Total deposits

$

4,588,551

4,524,038

4,337,441

4,096,898

3,966,192

   Total borrowed funds

$

738,628

770,838

796,077

800,577

816,848

   Total interest-bearing liabilities

$

4,182,398

4,106,315

3,941,876

3,757,588

3,607,156

   Shareholders’ equity

$

594,145

582,829

566,852

540,868

527,180

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mercantile-bank-corporation-announces-strong-first-quarter-2025-results-302432780.html

SOURCE Mercantile Bank Corporation